Online citations, reference lists, and bibliographies.
← Back to Search

Novel Albendazole-chitosan Nanoparticles For Intestinal Absorption Enhancement And Hepatic Targeting Improvement In Rats.

Yayuan Liu, Xiaoqing Wang, Wei-xin Ren, Yuanlan Chen, Y. Yu, J. Zhang, Dilimulati Bawudong, Jun-peng Gu, Xiao-dong Xu, X. Zhang
Published 2013 · Medicine, Materials Science

Cite This
Download PDF
Analyze on Scholarcy
Share
To improve the treatment of helminthiasis, filariasis, and colorectal cancer, albendazole-associated chitosan nanoparticles (ABZ-CS-NPs) were prepared using the emulsion crosslinking volatile technique with contained sodium tripolyphosphate as the crosslinking agent and Poloxamer 188 as the auxiliary solvent. The structural characteristics of the NPs were determined using X-ray diffraction to analyze the interaction between CS and the drug. The NPs were then evaluated in terms of their physicochemical characteristics, drug release behavior, in vivo pharmacokinetic parameters, and biodistribution in animal studies. ABZ-loaded NPs with a uniformly spherical particle sizes (157.8 ± 2.82 nm) showed efficient drug loading, encapsulated efficiency, and high physical stability. The drug release from ABZ-CS-NPs was extended over several periods. Kinetic models were then fitted to determine the release mechanisms. ABZ and its metabolite albendazole sulfoxide (ABZSX) were analyzed in rats with mebendazole as the internal standard using reversed-phase high-performance liquid chromatography. Compared with the ABZ suspension groups, the relative bioavailability values of ABZ and ABZSX were 146.05 and 222.15%, respectively. In addition, the plasma concentration versus time curve is consistent with that of the two compartment models in the plasma concentration versus time curve. The results indicate that the ABZ-loaded NPs are promising novel ABZ candidates for passive diffusion in the treatment of hydatid cysts in the liver via oral administration.
This paper references
10.1016/S0264-410X(03)00228-7
Chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen, Der p 1 for oral vaccination in mice.
J. L. Chew (2003)
10.1016/S0168-3659(02)00270-5
Oral bioavailability in sheep of albendazole from a suspension and from a solution containing hydroxypropyl-beta-cyclodextrin.
B. Evrard (2002)
10.1016/j.jconrel.2007.12.014
Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice.
J. Kim (2008)
10.4269/ajtmh.2011.11-0382
Long-term albendazole effectiveness for hepatic cystic echinococcosis.
J. Salinas (2011)
10.1016/J.IJPHARM.2005.01.042
Chitosan nanoparticles as a novel delivery system for ammonium glycyrrhizinate.
Yan Wu (2005)
10.1016/J.PARINT.2004.05.001
Effect of treatment with free and liposomized albendazole on selected immunological parameters and cyst growth in mice infected with Echinococcus multilocularis.
E. Dvorožňáková (2004)
10.1016/j.ejpb.2010.03.017
In vivo evaluation of albendazole microspheres for the treatment of Toxocara canis larva migrans.
M. G. Barrera (2010)
10.1002/JPS.2600800706
In vitro release and intestinal absorption of physostigmine salicylate from submicron emulsions.
A. Rubinstein (1991)
10.18433/J38W25
Osmotically controlled drug delivery system with associated drugs.
B. P. Gupta (2010)
10.1016/S0168-3659(00)00361-8
Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency.
H. Mao (2001)
10.1023/A:1012128907225
Chitosan and Chitosan/Ethylene Oxide-Propylene Oxide Block Copolymer Nanoparticles as Novel Carriers for Proteins and Vaccines
P. Calvo (2004)
10.3797/SCIPHARM.2007.75.63
Improvement of albendazole dissolution by preparing microparticles using spray-drying technique
F. Alanazi (2007)
10.1016/j.ijpharm.2007.11.040
Study on the hydatid cyst membrane: permeation of model molecules and interactions with drug-loaded nanoparticles.
Tri Truong Cong (2008)
10.1016/J.JCONREL.2005.03.021
Preparation of nanoparticles composed of poly(gamma-glutamic acid)-poly(lactide) block copolymers and evaluation of their uptake by HepG2 cells.
Hsiang-Fa Liang (2005)
10.1016/J.JCONREL.2007.04.009
Effect of polymer molecular weight on the tumor targeting characteristics of self-assembled glycol chitosan nanoparticles.
Kyeongsoon Park (2007)
10.1007/s00436-011-2256-0
Epidemiology and history of human parasitic diseases in Romania
R. Neghina (2011)
10.1016/0016-5085(93)90355-G
Percutaneous drainage versus albendazole therapy in hepatic hydatidosis: a prospective, randomized study.
M. Khuroo (1993)
10.1021/JS970300N
Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor.
D. Hauss (1998)
10.1080/02652040802365182
Preparation of aminoglycoside-loaded chitosan nanoparticles using dextran sulphate as a counterion
E. Lu (2009)
10.1002/1615-9314(20021101)25:15/17<1043::AID-JSSC1043>3.0.CO;2-5
Chiral analysis of albendazole sulfoxide enantiomers in human plasma and saliva using capillary electrophoresis with on-column absorption and fluorescence detection
F. Prost (2002)
10.1016/0035-9203(86)90392-5
Effect of albendazole sulphoxide on viability of hydatid protoscoleces in vitro.
J. B. Chinnery (1986)
10.1016/J.IJPHARM.2006.05.060
A less irritant norcantharidin lipid microspheres: formulation and drug distribution.
Wang Li-xin (2006)
10.4103/1319-3767.84493
Role of Albendazole in the Management of Hydatid Cyst Liver
Shams-ul-Bari (2011)
10.1016/j.nano.2009.07.006
Norcantharidin-associated galactosylated chitosan nanoparticles for hepatocyte-targeted delivery.
Q. Wang (2010)
10.1080/17458080903513284
Two modelling data analytical methods applied to optimise the preparation of norcantharidin chitosan nanoparticles
W. Zhang (2010)
10.1016/j.etap.2011.12.001
Pharmacokinetics and tissue residues of hydrochloric acid albendazole sulfoxide and its metabolites in crucian carp (Carassius auratus) after oral administration.
Zaijian Li (2012)
10.1016/j.yrtph.2009.09.015
The safety of chitosan as a pharmaceutical excipient.
P. Baldrick (2010)
10.1016/S0378-5173(01)00777-3
Lactosaminated and intact N-succinyl-chitosans as drug carriers in liver metastasis.
Y. Kato (2001)
10.1016/0378-5173(95)04411-6
Effect of drug release rate on bioavailability of different aspirin tablets
S. Torrado (1996)
10.2174/157341308783591834
Studies on the Drug-Loading Mechanism of Polybutylcyanocrylate Nanoparticle and its Stability of Thermodynamics
Zhang Xue-nong (2008)
10.1007/BF00278590
Albendazole kinetics in patients with echinococcosis: Delayed absorption and impaired elimination in cholestasis
J. Cotting (2004)
10.1016/S0378-5173(02)00267-3
Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles.
Tanima Banerjee (2002)
10.1016/S0378-5173(02)00559-8
Bioavailability and efficacy characteristics of two different oral liquid formulations of albendazole.
J. García (2003)



This paper is referenced by
10.1016/j.exppara.2019.02.002
Albendazole-lipid nanocapsules: Optimization, characterization and chemoprophylactic efficacy in mice infected with Echinococcus granulosus.
Gabriela V Ullio Gamboa (2019)
10.3390/ma8020486
Exploring the Preparation of Albendazole-Loaded Chitosan-Tripolyphosphate Nanoparticles
Bong-Seok Kang (2015)
10.1007/s13346-020-00806-4
Chitosan-based particulate systems for drug and vaccine delivery in the treatment and prevention of neglected tropical diseases
Sevda Şenel (2020)
10.1371/journal.pone.0207625
Chitosan-based nanodelivery systems applied to the development of novel triclabendazole formulations
D. Real (2018)
10.1007/s00436-018-5849-z
In vitro and in vivo effects of chitosan-praziquantel and chitosan-albendazole nanoparticles on Echinococcus granulosus Metacestodes
Negin Torabi (2018)
10.1371/journal.pntd.0006422
Progress in the pharmacological treatment of human cystic and alveolar echinococcosis: Compounds and therapeutic targets
M. Siles-Lucas (2018)
10.18632/ONCOTARGET.3436
Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells
Zhi-Jie Hou (2015)
10.1080/03639045.2018.1438459
Chitosan nanoparticles for the oral delivery of tenofovir disoproxil fumarate: formulation optimization, characterization and ex vivo and in vivo evaluation for uptake mechanism in rats
Joseph Shailender (2018)
10.1080/03639045.2018.1438461
Albendazole solution formulation via vesicle-to-micelle transition of phospholipid-surfactant aggregates
Zahari Vinarov (2018)
10.1007/s40005-015-0171-6
Determination of preparation parameters for albendazole-loaded nanoparticles using chitosan and tripolyphosphate
Bong-Seok Kang (2015)
10.2217/nnm-2017-0102
Nanoformulations of albendazole as effective anticancer and antiparasite agents.
F. Movahedi (2017)
10.22270/IJDRA.V1I2.108
EMERGING TRENDS IN ORAL BIOAVAILABILITY ENHANCEMENT
Sushama Talegaonkar (2018)
10.1007/s00214-020-02620-0
Effect of chitosan/albendazole nanocarriers’ solvation by molecular dynamics
Ana Carolina da Silva Costa (2020)
10.1517/21678707.2014.870033
Alveolar echinococcosis: evaluation of therapeutic strategies
D. Vuitton (2014)
10.1007/S40995-017-0150-Z
Albendazole and Praziquantel Chitosan Nanoparticles: Preparation, Characterization, and In Vitro Release Study
Negin Torabi (2018)
10.18632/oncotarget.17292
Repurposing Albendazole: new potential as a chemotherapeutic agent with preferential activity against HPV-negative head and neck squamous cell cancer.
F. Ghasemi (2017)
10.1080/10717544.2019.1692968
Nanoparticles for antiparasitic drug delivery
Yuzhu Sun (2019)
Semantic Scholar Logo Some data provided by SemanticScholar